Small cap News

H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.

Morningstar similarly called Starlink a “niche solution, not a telecom disruptor,” with a realistic $129 billion global market.

Outlook expects a U.S. launch before year-end and anticipates 12 years of market exclusivity.

Nio received about 18.24 million CXMT shares, though the stake is subject to an 18-month lockup.

Weekend chatter focused on ImmunityBio’s quiet July, with some bulls calling the silence the “quiet before the kraken.”

ASTS recently raised $1.15 billion to support growth and secure launch capacity as it remains heavily reliant on SpaceX.

A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.

VinFast targets at least 300,000 global deliveries this year, up from about 200,000 in 2025.

Analysts also became more bullish, raising price targets despite theater attendance remaining below pre-pandemic levels.

Sellas is preparing for database lock, potential BLA-related regulatory work, and development of SLS009, its second AML drug.

Investors expect stronger demand for domestic producers of rare earths and strategic materials.

The company entered a quiet period for trial-specific updates ahead of topline data.

IRDM benefited from Rocket Lab’s $8 billion takeover, while VSAT rallied on the value of its scarce spectrum assets.

Legal hurdle, AI spending and profit concerns weighed on sentiment.

Aron also said that this was the first time in AMC’s history that it crossed $300 million in adjusted earnings before interest, taxes, depreciation, and amortization in a quarter.

Short exposure jumped about $2 billion, or 26.7%, as drone firms became Wall Street battleground stocks.

ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.

Investors named Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly and Bristol Myers as possible bidders.

According to The Washington Post report, federal traceback investigators identified Taylor Farms as the supplier of shredded iceberg lettuce served at Taco Bell restaurants across five states tied to a Cyclospora outbreak.

Goldman sees major opportunities in space infrastructure, semiconductors, software and advanced materials.

CEO Angelos Stergiou said he will discuss “novel clinical developments” involving GPS and SLS009 on Fox & Friends.

Proceeds could fund launch partnerships or acquisitions, fueling speculation that ASTS may buy or invest in a rocket company.

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

VC Magnus Sigurdsson said a rival bidder is unlikely after AtaiBeckley’s months-long structured sale process.

Possible targets discussed by the analyst include ULA, Firefly, Relativity Space and Stoke Space.

According to TheFly, Morgan Stanley has an ‘Underweight’ rating and a $5 price target on Lucid, implying a 5% downside potential from current levels.

According to TheFly, HC Wainwright initiated coverage of Unusual Machines with a ‘Buy’ rating and a price target of $42.

BYD’s European market share more than doubled to 2.8% in May, surpassing Ford, Tesla and Nissan.

CXMT is China’s largest DRAM maker and ranks fourth globally. The IPO could raise 66.6 billion yuan, making it China’s second-largest ever.

Sheets Smith Wealth Management cut its IBRX stake by 7.2% to 512,572 shares.

The discussion is expected to cover the EMJX acquisition, future strategy and responsibilities.

CEO Angelos Stergiou said slower event accrual may signal a “highly effective active arm.”

SpaceX and AST SpaceMobile tied as retail traders’ top beaten-down space picks, with 33% each.

Investors tracked rising demand for autonomous warfare, drawing attention amid U.S.-Iran tensions.

Goldman forecasts 43% vehicle-volume growth and 60% revenue growth this year.

The new variant is expected to sit above the Model Y L, making it Tesla’s priciest Model Y in China.

Burry has disclosed major long bets in PayPal, Lululemon, Alibaba, JD.com, Adobe and Molina Healthcare.

Tema also built an $89.2 million ASTS stake ahead of its next BlueBird satellite launch, while RKLB became the largest of the three positions by value.

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

According to TheFly, HC Wainwright raised its price target on First Tracks to $44 from $30 while maintaining a ‘Buy’ rating.

The five-seat ES8 starts at 382,800 yuan, about 6% below the three-row version.

Retail traders are watching to see whether ImmunityBio could announce preliminary Q2 revenue, with some speculating that demand for Anktiva could drive sales above $55 million.

Carr said he is “bullish” on SpaceX's use of new airwaves to boost satellite-to-cell service and said the FCC is “open-minded” about direct wireless deals.

During an interview with CNBC, Lee said he believes the unwind in semiconductor and memory stocks could be in its later stages.

China NEV retail sales fell for a sixth straight month, dropping 9% year-over-year in June to 1.007 million units.

The firm raised its bull-case target to $293 from $185, implying a 252% upside, citing launch and connectivity opportunities after the Iridium acquisition.

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

The company’s rolling FDA application is underway, with final submission expected in Q4 and launch targeted for H1 2027.